Immunomodulators are typically used in patients with advanced or metastatic cancers, where traditional treatments have failed. They are also being explored in earlier stages of cancer and in combination with other therapies. Biomarkers such as PD-L1 expression are often used to identify patients who are likely to respond to immunomodulatory treatments.